Valuation : Zymeworks Inc.

Market Cap 2.01B 1.73B 1.62B 1.48B 2.79B 192B 2.8B 19.23B 7.5B 96.78B 7.53B 7.37B 321B P/E 2026 *
20.6x
P/E 2027 * 35.1x
Enterprise Value 2.01B 1.73B 1.62B 1.48B 2.79B 192B 2.8B 19.23B 7.5B 96.78B 7.53B 7.37B 321B EV / Sales 2026 *
6.6x
EV / Sales 2027 * 5.68x
Free-Float
92.08%
Yield 2026 *
-
Yield 2027 * -
1 day-2.55%
1 week-1.40%
Current month+28.85%
1 month+25.03%
3 months+10.95%
6 months+21.38%
Current year+7.37%
1 week 25.61
Extreme 25.6095
30.62
1 month 21.52
Extreme 21.52
30.62
Current year 21.52
Extreme 21.52
30.62
1 year 13.6
Extreme 13.6
30.62
3 years 6.02
Extreme 6.015
30.62
5 years 4.11
Extreme 4.11
37.19
10 years 4.11
Extreme 4.11
59.03
Manager TitleAgeSince
Chief Executive Officer 63 2022-01-04
Director of Finance/CFO 44 2026-03-31
Chief Tech/Sci/R&D Officer - 2024-11-30
Director TitleAgeSince
Chairman 63 2022-01-04
Director/Board Member 61 2019-05-31
Director/Board Member 52 2020-02-29
Date Insider Type Main position Quantity % Market Cap.
7/6/26 Free

Chief Operating Officer

939 0.0013%
5/13/26 Free

EVP, General Counsel

297,000 0.4027%
5/13/26 Other

EVP, General Counsel

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-2.55%-1.40%+90.50%+277.44% 2.01B
-1.59%-3.35%+64.49%+98.69% 69.54B
-1.34%-0.75%+48.56%+90.63% 64.97B
-8.37%-12.43%+0.14%-15.42% 25.64B
-2.35%-5.75%-12.17%+448.29% 25.89B
+0.30%-0.69%+63.18%+11.93% 26.51B
-0.96%+10.36%+278.86%+438.78% 20.22B
-0.51%+0.23%+33.71%-18.02% 19.98B
-1.91%-4.37%+13.33%+531.29% 15.69B
-1.47%+0.68%+43.67%+145.49% 13.49B
Average -2.08%-1.87%+62.43%+200.91% 28.39B
Weighted average by Cap. -1.94%-1.50%+57.39%+153.70%

Financials

2026 *2027 *
Net sales 304M 262M 246M 224M 422M 29.06B 424M 2.91B 1.14B 14.67B 1.14B 1.12B 48.64B 353M 305M 286M 261M 491M 33.78B 493M 3.39B 1.32B 17.05B 1.33B 1.3B 56.54B
Net income 121M 105M 97.99M 89.45M 169M 11.59B 169M 1.16B 454M 5.85B 455M 445M 19.4B 88.98M 76.68M 71.89M 65.63M 124M 8.5B 124M 853M 333M 4.29B 334M 327M 14.24B
Net Debt - -
Logo Zymeworks Inc.
Zymeworks Inc. is a biotechnology company. The Company is engaged in managing a portfolio of healthcare assets and developing a pipeline of multifunctional biotherapeutics to improve the standard of care for conditions, including cancer, inflammation, and autoimmune disease. Its antibody-drug conjugates (ADCs) include ZW191, ZW251, and ZW220. ZW191 is a clinical-stage ADC that targets folate receptor alpha-expressing tumors including ovarian cancer, endometrial cancer, and non-small cell lung cancer (NSCLC), which is built using bystander-active, TOPO1i payload technology, ZD06519. ZW251 is a clinical-stage ADC molecule designed for the treatment of glypican 3 (GPC3)-expressing hepatocellular carcinoma (HCC). ZW220 is an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer, built using bystander active TOPO1i payload technology, ZD06519. Its therapeutic platforms can be used to develop multifunctional fit-for-purpose biotherapeutics with bispecific capabilities.
Employees
231
Date Price Change Volume
26-08-28 US$28.27 -2.55% 542,190
26-08-27 US$29.01 -1.01% 625,158
26-08-26 US$29.31 +6.68% 1,215,804
26-08-25 US$27.47 -4.52% 2,076,726
26-08-24 US$28.77 +0.35% 824,551
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
28.27USD
Average target price
41.58USD
Spread / Average Target
+47.09%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ZYME Stock